Want to see OSTX full AI Analyst Report?
Top Page
OS Therapies Incorporated
(OSTX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.50
▼(-10.71% Downside)
Action:Reiterated
Date:09/09/26
The score is held down primarily by weak financial performance (no revenue, expanding losses, persistent cash burn, and negative equity), which raises funding risk. Technicals are a relative positive with price above key moving averages and a positive MACD. Valuation remains challenging due to negative earnings, and corporate events are mixed—supportive for liquidity but carrying dilution and financing-structure risk.
Positive Factors
Clinical funding flexibility
The new ATM facility gives OS Therapies a flexible mechanism to finance clinical trials and research over multiple quarters. Access to staged equity funding can support pipeline advancement without requiring a single large transaction, although future share issuance remains a consideration.
Negative Factors
No commercial revenue and widening losses
The absence of commercial revenue confirms that OS Therapies remains dependent on successful clinical and regulatory progress before establishing a product-based revenue stream. Expanded losses indicate that operating costs are rising ahead of commercialization, weakening near-term earnings quality.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical funding flexibility
The new ATM facility gives OS Therapies a flexible mechanism to finance clinical trials and research over multiple quarters. Access to staged equity funding can support pipeline advancement without requiring a single large transaction, although future share issuance remains a consideration.
Read all positive factors
OS Therapies Incorporated (OSTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$75.82M
Dividend YieldN/A
Average Volume (3M)620.11K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue GrowthN/A
EPS Growth-41.63%
CountryUS
Employees5
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.09
Shares Outstanding46,805,230
10 Day Avg. Volume502,728
30 Day Avg. Volume620,108
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-6.72
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.11
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-224.87
Enterprise Value/Ebitda-2.18
Forecast
1Y Price Target
$8.67Price Target Upside415.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$2.00M
OS Therapies Incorporated Business Overview & Revenue Model
Company Description
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, OSTX’s ability to generate sustainable operating revenue is typically tied to advancing its drug candidates and monetizing them through one or more of the following mechanisms: (1) out-licensing or pa...
OS Therapies Incorporated Financial Statement Overview
Summary
Income Statement
5
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
8
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -374.81K | -363.08K | -2.78K | -4.22K | -805.00 | -1.16M |
| EBITDA | -38.74M | -28.39M | -6.83M | -4.34M | -4.45M | -4.84M |
| Net Income | -39.37M | -28.75M | -8.88M | -7.79M | -6.25M | -7.42M |
Balance Sheet | ||||||
| Total Assets | 9.90M | 6.84M | 5.54M | 798.08K | 509.11K | 325.89K |
| Cash, Cash Equivalents and Short-Term Investments | 205.03K | 269.83K | 5.53M | 38.98K | 171.48K | 80.79K |
| Total Debt | 0.00 | 0.00 | 0.00 | 14.61M | 10.35M | 7.07M |
| Total Liabilities | 20.64M | 12.94M | 4.73M | 24.81M | 18.07M | 11.78M |
| Stockholders Equity | -10.84M | -6.10M | 811.49K | -24.02M | -17.56M | -11.45M |
Cash Flow | ||||||
| Free Cash Flow | -18.53M | -14.24B | -7.28M | -3.01M | -3.79M | -4.41M |
| Operating Cash Flow | -18.53M | -14.24B | -7.28M | -3.01M | -3.79M | -4.40M |
| Investing Cash Flow | 0.00 | -466.42M | 0.00 | 1.15K | 230.88K | 200.47K |
| Financing Cash Flow | 15.94M | 9.44B | 12.78M | 2.87M | 3.65M | 3.05M |
OS Therapies Incorporated Technical Analysis
Negative
1.68
Price Trends
1.64
Negative
1.70
Negative
1.58
Positive
Market Momentum
-0.02
Positive
44.31
Neutral
14.43
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSTX, the sentiment is Negative. The current price of 1.68 is below the 20-day moving average (MA) of 1.72, above the 50-day MA of 1.64, and above the 200-day MA of 1.58, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.31 is Neutral, neither overbought nor oversold. The STOCH value of 14.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OSTX.
OS Therapies Incorporated Risk Analysis
OS Therapies Incorporated disclosed 66 risk factors in its most recent earnings report. OS Therapies Incorporated reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our substantial indebtedness and limited cash resources could adversely affect our financial condition and ability to obtain additional financing, and a default under our Secured Notes could result in the loss of substantially all of our assets. Q2, 2026
2.
The terms of our Secured Notes impose significant restrictions on our operations and financing activities, which could limit our financial and operational flexibility. Q2, 2026
3.
An event of default under our Secured Notes could result in acceleration of our obligations and materially adversely affect our financial condition. Q2, 2026
OS Therapies Incorporated Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | $75.82M | -1.49 | 683.03% | ― | ― | -41.63% | |
48 Neutral | $85.28M | -1.06 | -70.14% | ― | ― | 16.04% | |
44 Neutral | $60.85M | -0.57 | -74.90% | <0.01% | ― | 44.73% | |
43 Neutral | $68.46M | -3.46 | -47.92% | ― | -75.00% | 74.04% | |
42 Neutral | $50.46M | -0.90 | -1266.43% | ― | ― | 49.43% |
* General Sector Average
OSTX
OS Therapies Incorporated
1.62
-0.45
-21.74%
IBIO
Ibio
1.13
0.28
32.51%
XBIT
XBiotech
2.19
-0.47
-17.67%
ACET
Adicet Bio
6.50
-9.50
-59.38%
ELTX
Elicio Therapeutics
1.92
-8.90
-82.26%
ACRV
Acrivon Therapeutics, Inc.
1.99
0.08
4.19%
OS Therapies Incorporated Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
OS Therapies Announces Prospectus for Secondary Share Resales
Neutral
Sep 10, 2026
On September 10, 2026, OS Therapies Incorporated filed a prospectus supplement with the U.S. Securities and Exchange Commission under its effective Form S-3 shelf registration, covering the potential resale from time to time of up to 5,874,094 sha...
Executive/Board ChangesShareholder Meetings
OS Therapies Stockholders Approve Incentive Plan and Board
Positive
Sep 9, 2026
On September 9, 2026, OS Therapies Incorporated stockholders approved an amendment and restatement of the company’s 2023 Incentive Compensation Plan at the 2026 annual meeting, reinforcing its ability to grant equity‑based awards to em...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
OS Therapies Launches $75 Million At-The-Market Offering
Positive
Aug 21, 2026
On August 21, 2026, OS Therapies Incorporated entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market equity offering program, allowing the company to sell up to $75 million of its common stock from time to time...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
OS Therapies Announces Convertible Note Financing and Warrants
Positive
Aug 12, 2026
On August 10, 2026, OS Therapies Incorporated closed the first tranche of a senior secured convertible note private placement of up to $10 million, issuing $5.405 million in principal notes, common stock, pre‑funded warrants and five‑y...
Business Operations and StrategyPrivate Placements and Financing
OS Therapies Settles Leonite Debt, Issues Bridge Financing
Neutral
Aug 6, 2026
On June 30, 2026, OS Therapies entered into a private placement with Leonite Fund I, LP for a senior secured convertible promissory note of up to $10 million, issuing 275,000 commitment shares and a five-year warrant for up to 1.75 million shares,...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
OS Therapies Ends At-The-Market Equity Sales Program
Negative
Jul 29, 2026
On July 23, 2026, OS Therapies Incorporated notified B. Riley Securities Inc. and JonesTrading Institutional Services LLC that it was terminating its At Market Issuance Sales Agreement, originally signed on August 8, 2025, with the termination eff...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.